of P e d i a t r i c s , Torrance, CA. To c h a r a c t e r i z e t h e ontogenesis of t h e hepatic EGF system i n normal Balb mice, we measured scrum and l i v e r concentrations of EGF, and l i v e r concentrations of pre-pro EGF mRNA and EGF recept o r binding. Male and female animals were studied a t 1,2,3,5,7 and 10 wks of l i f e . After s a c r i f i c e , body weight and length were measured an9 serum and l i v e r t i s s u e s were c o l l e c t e d f o r EGF determinations.
was low a t 1 , 2 and 3 wks increasing t o 5.03t0.83 and 5.7921.02 (fm/pg membrane p r o t e i n ) i n males and 1.8430.64 and 2.3620.28 i n females a t 5 and 10 wks respectively. Values were s i g n i f i c a n t l y lower (p<O.Olj i n females. Pre-pro EGF mRNA was examined a t 1,2,3,5,7 and 10 wks. EGF message increased i n l i v e r t o highest values a t 10 wks i n both males and females. Conclusions: There i s a p a r a l l e l increase of serum and l i v e r EGF concentrations, and l i v e r EGF mRNA between 5 and 10 wks of postnatal l i f e . EGF receptor binding a l s o increases during t h i s time. The r e s u l t s suggest t h a t newborn l i v e r may be an important source of c i r c u l a t i n g EGF i n Balb mice. ~r . :~h i l d r e n ' s iosPital'of pEad:lohla. Universitv ofPennsvlvania School of Medicine, b e p i r t m e n t of Pediatrics & Radiology, Philadelphia, PA Glucocorticoid therapy in CAI1 is titrated to maintain adequate adrenal suppression while avoiding the consequences of steroid excess. Although adrenal steroid levels may acutely reflect overdosage, chronic overtreatment is often suspected only after growth failure and retardation of bone age are noted. Osteo orosis i s a known complication of steroid therapy and h a s been dPescribed i n CAH. Photon absorbtiometry is a simple, precise and noninvasive method of measuring bone demineralization. It may afford a more sensitive measure of steroid overtreatment t h a n a bone age film, with less radiation exposure. We measured bone density i n 20 C A H g t i e n t s (10 males and 10 females) using the linear radiation model P-2 bone mineral analyzer and correlated the findings with steroid levels a s well as clinical aspects relnted to glucocorticoid treatment. Preliminary data show t h a t there is some correlation between bone density a n d glucocorticoid m a n a g e m e n t of CAH. All t h e gatients with elevated or borderline elevated adrenal steroid levels ad bone density values in the normal ran e 3 of 5 girls with biochemical values suggesting overdosage h a 2 tione density values i n t h e range consistent with demineralization. None of these 3 h a d a n y decline in growth velocity a n d bone ages done in 2 of the 3 showed n o dela . These preliminary data suggest t h a t bone densitometry may be orbenefit in monitoring therapy in CAH patients a n d may result in the earlier detection of oversuppression. To validate i t s e f f e c t , 4ugIkgl2X week SQ i n j e c t i o n s were given t o 8 males with delayed puberty.
OF T3 AND T4
After one month, urinary LH and FSll l e v e l s (ugl24h) were s i g n i f i c a n t l y greater the day a f t e r i n j e c t i o n than the day before (LII 41.8 t 6.5 vs 22.8 * 7.4, p < 0.003, FSH 63.5 + 9.0 vs 40.9 * 11.9, P < 0 . 0 l i ) .
During childhood, inappropriate gonadotropin secretion may not he apparent and the diagnosis of gonadal f a i l u r e may not be posslble.
The use of intermittent LHKH analogue as an agonist in s i x prepubertal male children, aged 5-12y, resulted in a r i s e of L H and FSH over 6 weeks. FSH without s i g n i f i c a n t testosterone response. This demonstrates an abnormal feedback mechanism in childhood. This procedure may be a tlseful diagnostic t e s t f o r evidence of gonadal f a i l u r e in children. Sex s t e r o i d hormones can accelerate l i n e a r growth i n children with growth hormone (GI{) deficiency (GHD) without GI1 therapy. m e r e f o r e , GHD may not be suspected i n children who a r e i n puberty. LHRH analogue (LBRtIa) therapy i n children with precocious puberty (PP) has been demonstrated t o decelerate the rapid growth velocity associated with elevated sex s t e r o i d hormones. W e report two children below with PP i n whom GHD was diagnosed a f t e r t h e i r l i n e a r growth was decelerated by i n t r anasal administratior of LIiNia ( N a f a r e l i n ) . CA=chronological age i n years; BA=bone age i n years; GR=growth r a t e i n cm/year: a=before LHRHa therapy, b=during LHRHa therapy, c=combined LHRHa and GH therapy GHD i n children with PP may be more common than suspected previously. Recognition of t h i s f a c t i s important s i n c e a major complication of PP i s s h o r t s t a t u r e a s an a d u l t . The combination Of GI4 and LHRHa therapy provided a more normal growth velocity f o r these children. These findings suggest t h a t f o r some children with GHD, LHWa therapy may be indicated t o optimize t h e i r f i n a l a d u l t height.
GROWTH HORMONE DEFICIENCY IN
( Children w i t h Turner syndrome (TS) frequently have asymtmat i c osteoporosis by radioiogic diagnosis. Growth hormone (GH) has been considered a s a therapeutic or preventive measure for osteoporosis. GH a l s o has been demonstrated t o be e f f e c t i v e i n improving growth velocity i n children w i t h TS. This study was designed t o determine t h e changes i n bone density associated with GH therapy.
Eight children with TS (45,X i n 3; 45,X/46X,Xq i n 1 ; 45,X/46, X,idic(X) i n 1; 45,X/46,X, idic(Y) i n 1; 45,X/46X,rX(pllq22); and 45,X/46X,iso(Xq) i n 1 ) were studled between chronological ages of 7 t o 13 wlth bone ages of 3 t o 1 1 years. The bone density changes were assessed by dual beam photon densitometry wlth a program modified for children. The area studied was L2-L4. Bone density was measured every 6 months. Each p a t i e n t served as her own control for 6 months before GH therapy was s t a r t e d . GH was administered intramuscularly t h r e e times weekly a t a dosage of 0.125 mg/Kg/dose. Changes i n one density a t 6 months of con-! !
